Inflammatory markers and cardiometabolic diseases (Q38535519)

3 September 2017

1 reference

title

Inflammatory markers and cardiometabolic diseases (English)

1 reference

3 September 2017

N Esser

1

1 reference

3 September 2017

N Paquot

series ordinal

2

1 reference

3 September 2017

A J Scheen

series ordinal

3

1 reference

3 September 2017

language of work or name

1 reference

1 June 2015

1 reference

3 September 2017

1 reference

3 September 2017

70

1 reference

3 September 2017

3

1 reference

3 September 2017

193-199

1 reference

Pathophysiology of type 2 diabetes

3 September 2017

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Type 2 diabetes mellitus: a metabolic autoinflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Banting lecture 1988. Role of insulin resistance in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collab

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Inflammation in atherosclerosis: from pathophysiology to practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Anti-inflammatory therapies for cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Interaction between cytokines and inflammatory cells in islet dysfunction, insulin resistance and vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Emerging anti-inflammatory drugs for atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Insulin sensitizers in 2013: new insights for the development of novel therapeutic agents to treat metabolic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Obesity phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Inflammation and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Ectopic lipid storage and insulin resistance: a harmful relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Cross-talk between skeletal muscle and immune cells: muscle-derived mediators and metabolic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Myokines in insulin resistance and type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Macrophages and islet inflammation in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Toll-like receptors and NLRP3 as central regulators of pancreatic islet inflammation in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Inflammation in obesity and diabetes: islet dysfunction and therapeutic opportunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Evaluation of the immune response to pneumococcal capsular polysaccharides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Roles for chemokines in liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Obesity, fatty liver disease and intestinal microbiota

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Microbiota, inflammation and obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Interaction between obesity and the gut microbiota: relevance in nutrition

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Microbiota and diabetes: an evolving relationship.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Immune mechanisms in atherosclerosis, especially in diabetes type 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Is inflammation a common retinal-renal-nerve pathogenic link in diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Mechanisms of diabetic complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Role of inflammation in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Pathophysiological role and therapeutic implications of inflammation in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Therapeutic interventions against inflammatory and angiogenic mediators in proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Chemokine mediated monocyte trafficking into the retina: role of inflammation in alteration of the blood-retinal barrier in diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Anti-inflammatory cytokines and risk of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

C-reactive protein, fibrinogen, and cardiovascular disease prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates?

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

The effects of diet on inflammation: emphasis on the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

The immune protective effect of the Mediterranean diet against chronic low-grade inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Systematic review of saturated fatty acids on inflammation and circulating levels of adipokines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Unsaturated fatty acids prevent activation of NLRP3 inflammasome in human monocytes/macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Free fatty acids as modulators of the NLRP3 inflammasome in obesity/type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Associations between dietary inflammatory index and inflammatory markers in the Asklepios Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Mediterranean dietary pattern, inflammation and endothelial function: a systematic review and meta-analysis of intervention trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Effects of fibrates on C-reactive protein concentrations: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Reduction of C-reactive protein is not associated with reduced cardiovascular risk and mortality in patients treated with statins. A meta-analysis of 22 randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

The Renin-Angiotensin-aldosterone system in vascular inflammation and remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

New therapeutic approaches in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Mechanisms behind the anti-inflammatory actions of insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

"Anti-inflammatory" drugs and their effects on type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Anti-inflammatory therapy in chronic disease: challenges and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Targeting inflammation in the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Mechanisms of disease: inflammasome activation and the development of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Inflammasome and cytokine blocking strategies in autoinflammatory disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

Targeting inflammation in the treatment of type 2 diabetes: time to start

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F2295333715Y.0000000004

10.1179/2295333715Y.0000000004

21 January 2018

Identifiers

DOI

1 reference

3 September 2017

1 reference